Alto Neuroscience (Alto Neuroscience) Debt-to-Revenue : N/A (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Alto Neuroscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.20 Mil. Alto Neuroscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $8.81 Mil. Alto Neuroscience's annualized Revenue for the quarter that ended in Mar. 2024 was $0.00 Mil.

Alto Neuroscience Debt-to-Revenue Historical Data

The historical data trend for Alto Neuroscience's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Debt-to-Revenue Chart

Alto Neuroscience Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Revenue

N/A

Alto Neuroscience Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial			N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Alto Neuroscience's Debt-to-Revenue

For the Biotechnology subindustry, Alto Neuroscience's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alto Neuroscience's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alto Neuroscience's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Alto Neuroscience's Debt-to-Revenue falls into.

Alto Neuroscience Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Alto Neuroscience's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.125	+	9.861)	/	N/A
	=	N/A

Alto Neuroscience's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.201	+	8.812)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Alto Neuroscience Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Alto Neuroscience (Alto Neuroscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus

Steven Cohen's Point72 Asset Management Buys New Stake in Alto Neuroscience Inc

By GuruFocus Research • 02-08-2024